reason report
sanofi bet dupi collabor streamlin pt
capit market day announc long-term guidanc
dupix dupilumab higher peak
consensu sale current annual
sale partner also restructur commerci
partnership kevzara sarilumab arthriti praluent
alirocumab hyperlipidemia bring need clariti
regn financi statement immedi enhanc
profit joint antibodi collabor agreement
sign like accord sanofi sanofi
assum global kevzara right royalti also
ex-u praluent right get royalti take
us right praluent thu opportun exist
regeneron antibodi partnership profit becom significantli
profit immedi net effect cours depend
manag promot expens praluent
imposs regeneron profit could initi go
result chang increas dupi spend weigh
partnership increas praluent spend us despit
regard posit long-term chang
updat model mani move part less collabor
payment less expens fewer product dupi price target
mani detail new collabor
arrang disclos even final could
materi impact forecast taken preliminari step updat
compani model valuat reflect like new term
antibodi collabor sg expens estim come materi
antibodi collabor profit increas
howev updat sanofi sg reimburs
estim reduc lead decreas
sanofi collabor revenu forecast updat sanofi
collabor revenu forecast lower
total revenu forecast increas remain larg
unchang includ us praluent product sale
kevzara ou praluent royalti incom expens side
reduc sg estim reflect
cost save kevzara potenti praluent well cog
estim went primarili due inclus us praluent
royalti payment total estim oper expens lower
oper margin higher benefit higher profit
antibodi collabor program dupix result
chang increas ep price target
increas reiter op
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv iqvia inc
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success first truli
novel medicin dupix allerg diseas first product eylea continu surpris
investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab remain posit eylea expect continu grow
lose market share emerg competitor novarti beovu
excit aspect compani next wave innov antibodi notabl
dupix approv adult atop dermat asthma like receiv
label expans multipl allerg diseas indic expect dupix dupilumab
gener revenu peak signific upsid
indic longer term regeneron wholli own antibodi could contribut
meaning revenu earn growth period current compani
invest mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv
period profit antibodi collabor sanofi begin accumul
new sanofi ceo paul hudson highlight key reason dupix bullish in-lin
thesi
sanofi consid dupix rare asset type inflamm offer specif control
key element immun system excel safeti profil profil optim
suit diseas often manifest younger patient mani current
autoimmun biolog would recommend due safeti risk furthermor sanofi
believ dupix suitabl less sever patient also typic avoid biolog due
poorer risk/benefit forthcom jak sanofi ceo believ dupix put jak
inhibitor place diseas larg shut mani compon
immun system carri significantli larger safeti risk compar biolog
specif sanofi maintain efficaci match dual inhibit
provid dupix final first-mov advantag atop dermat
multipl potenti allerg indic give sanofi confid dupix guidanc
dupix adult atop dermat penetr despit annual sale
sanofi estim penetr dupix atop dermat year-old label reach
patient us penetr rate adult year-old
level leav unpenetr patient biolog elig sanofi also believ
addit patient years-old becom elig label
expans
asthma dupix reach us patient biolog share
sanofi estim address patient suggest patient
elig us biolog biolog penetr howev dupix
patient biologic-nav drug expand market directli
compet us base iqvia new brand prescript nbrx data dupix
outpac launch recently-approv asthma nucala mepolizumab
fasenra benralizumab expect sell combin
dupix clinic develop six new potenti indic
sanofi announc new dupix phase iii three dermatolog indic prurigo nodulari
submiss bullou pemphigoid submiss chronic spontan urticaria
submiss well respiratori condit allerg bronchopulmonari
aspergillosi submiss addit previous announc phase iii
eosinophil esophag submiss chronic obstruct pulmonari diseas
submiss told indic could increas number us patient elig
dupix sanofi confirm indic apart copd
incorpor long-term revenu forecast appear comment
expect revenu ultim still come atop dermat asthma
updat develop
sanofi regeneron continu jointli develop year
compani report combin dupix demonstr increas
benefit compar dupix monotherapi chronic obstruct pulmonari diseas copd
monotherapi show better result dupix monotherapi see note
mechan anoth setback year report
etokimab fail meet primari endpoint atla phase studi moderate-to-sever
atop dermat see colleagu note sanofi regeneron announc
still evalu potenti path forward asset yet decid termin
advanc asset
collabor restructur enhanc dupix profit remov
kevzara praluent burden
sanofi regeneron plan restructur antibodi commerci collabor
sanofi receiv global right kevzara regeneron receiv royalti regeneron
receiv us right praluent pay royalti sanofi role switch ex-u
howev chang dupix commerci dynam regeneron sole
respons fund develop commerci expens us praluent
contribut noth ex-u praluent global kevzara restructur immedi
reduc signific portion collabor sg regeneron shoulder
incom statement allow regeneron right-siz commerci spend praluent
commensur run-rat without burden oversight joint steer
committe net effect chang depend much praluent promot
regeneron implement price changeov partnership
old structur reach profit larg basi dupix
offset loss kevzara praluent
posit stock impact mute announc sanofi may sell stake
decemb lock-up liquid like take multipl year
despit bullish dupix commentari guidanc consensu regn stock
impact in-lin broader biotech ibb perform yesterday like due
recent file announc sanofi ownership share
outstand share lock-up date decemb sanofi may seek sell
share lock-up expir market react neg potenti disrupt
liquid event sanofi manag event suggest sell stake
see compel invest opportun plan liquid immedi without
specif need cash addit accord regeneron case sanofi decid
liquid stake process like take multipl year base certain provis
two compani
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani rhhbi nv
novo earn multipl ep appli current
ep estim give valu use high growth revenu
multipl similar compani nv sni azn novo rhhbi
consensu sale appli revenu estim
give valu lastli dcf valuat given wacc termin cash
flow growth rate give present valu averag three method
current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand price pressur compani cholesterol treatment praluent lastli
compani convert rel littl revenu cash flow today histori return
cash investor ultim may undermin valu stock investor
willing continu
brand
type event
event trial detail
date known
up/down
expect
phase registr
us regulatori file
svb leerink llc equiti research compani file
combo immunotherapi present
futur medic confer
interim analysi os expect
libtayo mono
manag report phase data futur
phase result follow safeti
end
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap growth biotech ep multipl
ep rhhbi nv novo
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl appli expect
revenu
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
